Evotec (ETR:EVT) Stock Passes Below 50-Day Moving Average – Here’s Why

Evotec SE (ETR:EVT) shares passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of €4.11 and traded as low as €3.33. Evotec shares last traded at €3.36, with a volume of 632,201 shares traded.

Evotec Stock Performance

The company has a quick ratio of 2.97, a current ratio of 2.33 and a debt-to-equity ratio of 71.50. The stock has a 50 day simple moving average of €4.11 and a 200 day simple moving average of €4.79. The company has a market capitalization of $622.69 million, a price-to-earnings ratio of -3.63, a P/E/G ratio of 0.98 and a beta of 1.26.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.